What it sells
Gene-reactivating RNA platform.
Business model breakdown
Workflow: what inputs become what output?
Short RNA oligonucleotides (aptaDiR) sequester DNMT1 to inhibit methylation globally; gene-specific variant (captaDiR) fuses a locus-targeting sequence to reprogram methylation at chosen genes.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-30 | Seed | EUR 40M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.